References
- Musto P, Fraticelli VL, Mansueto G, et al. Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon. Leuk Lymphoma 2015;56:1510–1513.
- Zschiesche W, Augsten K, Ozegowski W, et al. Alkylating anticancer agents and phagocytosis. I. Effects of a homologous series of 1,2-substituted 5-bis(beta-chloroethyl)-amino-benzimidazole derivatives on carbon clearance. J Reticuloendoth Soc 1970;8:538–549.
- Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287–1288.
- Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006;132:205–212.
- Ponisch W, Moll B, Bourgeois M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 2013;139:1937–1946.
- Ponisch W, Holzvogt B, Plotze M, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol 2014 June 19. [Epub ahead of print]
- Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 2013;3:e162.
- Mele G, Spina A, Guaragna G, et al. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma. Leuk Lymphoma 2014;55:1191–1193.
- Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985–991.